Elon Musk says Neuralink’s brain implant for the blind is complete from an engineering standpoint. But no human trial has been registered, no patient has received one, and the timeline for a first implant has slipped more than once.

Neuralink’s Blindsight, a brain implant designed to give some vision to people who are blind, is finished from an engineering standpoint and is waiting only on regulatory approval, Elon Musk says.
Musk first made the claim in a post on X on October 30, writing that Blindsight “will, as the name suggests, enable even those who are completely blind or have never seen to see. It is ready from an engineering standpoint. Just waiting on regulatory approval.” He repeated the message in another post on November 20, again without giving a date.
The same day, Neuralink shared a video of a participant in its separate paralysis trial playing the newly released Grand Theft Auto VI using only a brain implant.
How Neuralink’s Blindsight is meant to work
Blindsight skips the eyes and the optic nerve completely. A camera, possibly built into a pair of glasses, captures the scene in front of the user. A processor turns that image into a pattern of electrical signals, which is sent wirelessly to a tiny array of electrodes implanted in the visual cortex at the back of the brain.
When those electrodes stimulate brain cells, the person perceives small points of light called phosphenes. The idea is that, with practice, the brain learns to read those points of light as shapes, edges and movement.
Because it works directly on the brain, Neuralink says Blindsight could help people who have lost both eyes or their optic nerves, and possibly people who have been blind from birth, as long as the visual cortex itself is intact.
Musk has been clear that the first version will be crude. He has compared early Blindsight vision to “Atari graphics” and “early Nintendo graphics,” and has said resolution could improve over time with more electrodes and better software.
Breakthrough designation is not approval
The U.S. Food and Drug Administration (FDA) gave Blindsight Breakthrough Device Designation in September 2024. That status is meant to speed up development and review of devices for serious conditions, and it gives the company closer contact with FDA experts.
It is not approval to sell the device, and it does not mean the FDA has found it safe or effective. Before Blindsight can reach patients, it would first need permission to begin human trials, and then evidence from those trials.
As of early November, no Blindsight or vision-restoration study from Neuralink was listed on ClinicalTrials.gov, the U.S. government’s public trial registry, where the company has posted its other studies. Neuralink has not named a trial site, and no one has yet received a Blindsight implant.
Neuralink has not published peer-reviewed evidence of vision restoration. At a June 2025 conference, a company engineer reported that monkeys with the implant moved their eyes toward the stimulated location in at least two-thirds of trials. That suggests the animals perceived something, but no paper detailing those results has been released.
A timeline that keeps moving
Musk’s predictions for the first human Blindsight implant have shifted. In March 2025 he reportedly said he hoped to perform it that year. In June 2025 he put it six to 12 months away, and Neuralink said it planned to welcome its first Blindsight participant in 2026. In January 2026 he said the company was ready “pending regulatory approval.” With six weeks left in 2026, that first implant has not been announced.
Musk has a long history of ambitious Neuralink timelines. He predicted human trials on at least four occasions starting in 2019, before the FDA rejected the company’s first application in 2022. The agency approved Neuralink’s first human study in May 2023.
Telepathy and Blindsight
Neuralink’s first product, Telepathy, reads signals from the brain. It lets people with paralysis control a computer cursor, and in some cases games, keyboards or robotic arms, by imagining moving their hands. Its studies are running in the United States, Canada, the United Arab Emirates and the United Kingdom.
Blindsight works in the opposite direction, writing signals into the brain. Both devices remain investigational and neither is approved for general use.
If regulators allow trials to begin and the device proves safe and useful, Blindsight could offer a new option to people whose blindness comes from damage to the eyes or optic nerves. For now, the claim that it is ready rests on Neuralink’s own word. The proof will come from human trials that have not yet started.
Sources: Elon Musk on X (October 30 and November 20, 2026); Tom’s Hardware; TechNewsWorld; Interesting Engineering; XenoSpectrum; Drug Development & Delivery; ClinicalTrials.gov; Reuters (2023).
More technology coverage from VPN: AI giant Anthropic prices IPO ahead of Nasdaq debut.




Leave a Reply